Impact of High Loading Dose of @entity2993 in XXXX @entity1 with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial.

@entity1 @entity8 @entity6 @entity2993 @entity740 @entity1011
INTRODUCTION: The effectiveness of statin pretreatment in reducing the incidence of contrast induced @entity8 has been examined in some observational and randomized studies, yielding controversial results. AIM: This study sought to evaluate the role of @entity2993 in prevention of contrast induced @entity8 in @entity6 @entity1 with mild to moderate @entity740 , undergoing elective percutaneous coronary intervention. METHODS: 130 @entity1 with mean glomerular filtration rate of 48.5    16 mL/minute/1.73m(2) were prospectively enrolled, then randomly (double blind) assigned in 1:1 ratio to receive @entity2993 (80 mg daily for 48 hours) or placebo. Serum @entity1011 _ glomerular filtration rate were measured pre-intervention, 72 hours and 10 days thereafter. An increase in serum @entity1011 by >0.5 mg/dL (44.2  mol/l), or >25% of baseline value was considered as contrast induced @entity8 . RESULTS: Mean age of the study cohort was 56    5 years (males: 62%). Mean serum @entity1011 level in the placebo group increased significantly 3 days after coronary intervention and declined on the 10(th) day to a level that did not differ significantly from the baseline level, but still higher. However, in @entity2993 group, mean serum @entity1011 level showed a non significant rise on the third day and then decreased to a level close to the baseline one, on the 10th day. Incidence of contrast induced @entity8 was 7.7% in @entity2993 group _ 20% in the placebo group (P<0.05). CONCLUSION: @entity2993 dose of 80 mg per day for 48 hours is associated with decreased incidence of contrast induced @entity8 in @entity6 @entity1 with @entity740 undergoing percutaneous coronary intervention. This article is protected by copyright. All rights reserved.
